ArticleInfection and drug resistance2026
Clinical Characteristics and Outcomes of Carbapenem-Resistant Gram-Negative Bacteria Pneumonia in Immunocompromised ICU Patients: A Retrospective Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunocompromised patients are increasingly admitted to intensive care units (ICUs), where carbapenem‑resistant Gram‑negative bacteria (CRGNB) pneumonia poses a growing threat due to limited treatment options and high mortality. This study aimed to compare the characteristics and outcomes of immunocompromised and immunocompetent ICU patients with CRGNB pneumonia and identify risk factors for ICU mortality. Methods: We retrospectively analyzed the clinical characteristics, laboratory findings, and outcomes of patients with laboratory‑confirmed CRGNB pneumonia admitted to Third Affiliated Hospital of Sun Yat‑sen University from January 2021 to April 2025. Results: Among 185 patients, 83 (44.9%) were immunocompromised, most often due to corticosteroid use (33.7%) or cancer chemotherapy (27.7%). Compared with immunocompetent patients, immunocompromised patients had higher rates of viral co-infection (36.1% vs 20.6%, p = 0.029), bacteremia (39.8% vs 15.7%, p < 0.001), and ICU mortality (65.1% vs 26.5%, p < 0.001). Escalation therapy was observed more commonly in immunocompromised patients (79.5% vs 61.8%, p = 0.014). In multivariate analysis, ICU mortality among immunocompromised patients was independently associated with vasopressor therapy (OR = 4.53, 95% CI: 1.35-16.85, p = 0.01), the ratio of invasive mechanical ventilation time to ICU length of stay (IMV time/ICU LOS) (OR = 1.18, 95% CI: 1.01-1.40, p = 0.04), age > 65 years (OR = 3.59, 95% CI: 1.20-12.14, p = 0.02), and platelet count < 100 × 10 Conclusion: Immunocompromised ICU patients with CRGNB pneumonia have distinct clinical characteristics, higher mortality, and risk factors that should be incorporated into prognostic evaluation and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.